INTRODUCTION
In the last decade there has been increasing prevalence of infections caused by multidrug-resistant organisms (MDRO), including by multidrug-resistant Acinetobacter baumannii. MDRAB is among the most difficult antimicrobial-resistant gram-negative bacilli to manage. Most common healthcare-associated infections caused by MDRAB are nosocomial pneumonia (especially ventilation pneumonia), central venous catheter infections, urinary tract infections, surgical site infections, skin and soft tissue infections and meningitis (Maragakis and Perl, 2008) . Bacteraemia often develops leading to invasive infection (when bacteria are isolated from blood and/or cerebrospinal liquor) with a bad prognosis.
Bacteremia is a very common complication, especially in ICU due to catheter colonisation. Usually it develops on av-PROCEEDINGS OF THE LATVIAN ACADEMY OF SCIENCES. Section B, Vol. 70 (2016) , No. 4 (703), pp. 232-236. DOI: 10.1515 /prolas-2016 erage 26 days after admission (Peleg et al., 2008) . Depending on the source, Acinetobacter baumannii accounts for about 1.5 to 2.4% of healthcare associated bloodstream infections. In France, Acinetobacter baumannii accounted for 12% of bloodstream infections (Fournier and Richet, 2006) . Over 90% of infections with Acinetobacter baumannii are recognised to be hospital-acquired, while only 4% are community-acquired, mostly pneumonia cases. In general, Acinetobacter baumannii accounts for a mortality rate in ICU of about 60%. There are few studies that provide exact numbers of infected persons, as it is very difficult to discern true infection from only colonization. The biggest problem is, when MDRAB is recognized, how to treat it?
In 2014, WHO released a publication on the threat of increasing antimicrobial resistance (Anonymous, 2014b) . The main focus was on carbapenems, as this antimicrobial agent is mostly used as last resort for treating many infections. In 2009, European surveillance data showed that 17% of bacteremia infections in ICU and almost 12% of UTI infections in ICU were caused by Acinetobacter spp.
Highest data was seen in Italy, Lithuania, and Slovakia. Survey has been conducted in several countries of resistant strains of Acinetobacter baumannii isolates, and up to 80% of strains have proven to have carbapenem resistance and 47% imipenem resistance. US-wide surveillance data showed that prevalence of carbapenem-resistant strains has increased from 5.2% in 1999 to 40.8% in 2010.
Acinetobacter baumannii (genospecies 2 of the ACB complex -A. calcoaceticus-A. baumannii) is the most resistant strain of Acinetobacter spp. It harbours various genes, which makes it resistant to multiple antimicrobial agents, the most common being: beta-lactamase genes (genes coding for aminoglycoside-modifying enzymes), disinfectantsulfanilamide resistance (qacEDelta1-sul1) genes, class 1 integrase (intl1) gene, the qnr gene associated with plasmidmediated quinolone resistance, and OXA-type genes for carbapenem-resistance (type 51 (Europe), and 23 and 58 (USA) being the most common ones) (Anonymous, 2014b) .
Septic shock develops in up to one-third of patients with bacteraemia. There is a trend of increasing MDRAB resistance to various widely used antibiotics and sometimes few options are available for saving a patient's life. Timely implementation of infection control measures, such as hand hygiene (Gould et al., 2010) , control of central venous catheter insertion protocols (Bishop et al., 2007; Anonymous, 2012b ) and hospital environmental MDRAB infection control (Anonymous, 2003; Obeidat et al., 2014) are extremely important to decrease spread of MDRO including MDRAB in the hospital environment and also decrease carriage of MDRO in out-patient setting. Data were collected based on clinical situations, and cultures were taken from blood, cerebrospinal fluid, bronchial specimens and swabs from wounds.
MATERIALS AND METHODS

Rîga
Bacteria identification and antibiotic susceptibility testing were performed using a VITEK 2 compact, BioMerieux, France.
Acinetobacter baumannii isolates were tested for sensitivity to ampicillin-sulbactam (SAM), piperacillin-tazobactam (TZP), ceftazidime (CAZ), cefepime (FEP), imipenem (IPM), meropenem (MEM), amikacin (AMK), gentamicin (GEN), tobramycin (TOB), ciprofloxacin (CIP), colistin (COL) and tigecycline (TGC).
Acinetobacter baumannii isolates were considered as multi-drug resistant (MDRAB) if bacteria showed combined resistance to ampicillin-sulbactam (SAM), piperacillin-tazobactam (TZP), antipseudomonal cephalosporins (CAZ, FEP), fluoroquinolones (CIP), aminoglycosides (AMK, GEN, TOB) and carbapenems (IPM, MEM).
Infection based on MDRAB-related infection was confirmed on the basis of case definitions of healthcareassociated infections (Anonymous, 2012a) .
Data were processed with statistical software WHONET 5.5.
RESULTS
In the time period from 2009 to 2013, prevalence of MDRAB in Rîga East University Hospital Clinical Centre Gaiïezers increased from 71 to 207 cases per year, followed by a decrease to 113 cases in 2015 (Fig. 1) . The maximum number of cases was observed in 2013 when 217 isolates were recorded.
Compared to the situation in other clinical centres of Rîga East University Hospital -Biíernieki (BIK), Linezers (LIN), Oncology Centre of Latvia (LOC), Latvian Centre of Infectious Diseases (LIC), and Centre of Tuberculosis and Lung Diseases (TBC), the decrease prevalence of MDRAB in the clinical centre Gaiïezers has been most prominent (Fig. 2) .
The proportion of bloodstream and CNS infections by MDRAB was 15.85% or 78 cases (Table 1 ).
In 2013, there were 33 MDRAB isolates from blood and cerebrospinal fluid indicating invasive infection while in 2014 this number decreased to 26 and further to 19 cases in 2015.
A decreasing tendency occurred between 2013 and 2015 in cases of MDRAB infection (Fig. 3 ).
All patients with bloodstream infections and central nervous system infections were treated with colistin, which was administered via intravenous and intrathecal routes for patients with meningitis.
In patients with bloodstream infections and central nervous system infections, resistance of Acinetobacter baumannii to various antibiotics was reported in 2013 to occur in over 80% of cases (Table 2) . In REUH, colistin is mainly used to treat infections caused by Acinetobacter baumannii and resistant strains reached very high numbers in 2013.
In 2014, resistance of Acinetobacter baumannii to various antibiotics was reported to be above 90% in most cases, which was an alarming increase compared to the level in previous years (Table 3) .
Comparing data from 2013 and 2014, resistance of Acinetobacter baumannii increased to imipenem, ciprofloxacin and colistin, while decreased slightly to amikacin. Resistance to colistin increased from 0% (95% CI = 0.0-13.7) in 2013 to 4% (95% CI = 0. 
